(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 meeting’s proffered paper session for non-prostate genitourinary tumors included a discussant presentation by Dr. Srikala Sridhar of the phase 2 NORSE trial assessing erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations. Dr. Sridhar started by highlighting the treatment landscape of metastatic urothelial carcinoma as it stands in 2021, noting that we now have first through fourth-line therapies, stratified by platinum eligible versus ineligible: